MedTrace Logo

Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

NCT07347626 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 786

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Eptifibatide (Integrilin)

Participants will receive intravenous eptifibatide (135 μg/kg bolus, followed by 0.75 μg/kg/min infusion for 2 hours) initiated within 60 minutes after completion of standard intravenous thrombolysis (either alteplase or tenecteplase). Antiplatelet therapy with aspirin (100 mg) and/or clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.

DRUG

Standard Medical Therapy

Participants will not receive intravenous eptifibatide after completion of standard intravenous thrombolysis. Antiplatelet therapy with aspirin (100 mg) and/or clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.

Sponsors & Collaborators

  • The First Affiliated Hospital of Hainan Medical College

    collaborator UNKNOWN

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • Zhongming Qiu, MD · Xinqiao Hospital of the Army Medical University

  • Zhenqiang Zhao, MD · The First Affiliated Hospital of Hainan Medical University

  • Daojun Hong, MD · The First Affiliated Hospital of Nanchang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2029-09-30
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07347626 on ClinicalTrials.gov